ARTICLE | Clinical News

Avicidin data

May 30, 1995 7:00 AM UTC

NERX (Seattle) reported Phase I data showing tumor regressions and no dose-limiting toxicities in an ongoing, dose-escalation study of the antibody injected prior to radiation delivery.

A single dose gave evidence of tumor regression in three of six patients with large tumors and malignant ascites. However, regression in these bulky, chemotherapy-resistant tumors didn't reach the 50 percent required to qualify as partial responses. ...